Chugai Pharmaceutical

Roche's answer to AstraZeneca PNH drugs nabs China nod

China has become the first country to sign off on Roche’s PNH drug crovalimab, a subcutaneous answer to AZ’s infused treatments Soliris and Ultomiris.

Kevin Dunleavy Feb 8, 2024 11:02am

Roche sues Biogen over Actemra biosimilar infringement claims

Jul 17, 2023 9:45am

Roche's Chugai pays $25M to access subcutaneous delivery tech

Mar 29, 2022 8:05am

Taiho, Otsuka, Chugai, Biocon and Mark Alles—FiercePharmaAsia

Jan 10, 2020 10:59am

Chugai promises no supply interruption of cancer drug

Sep 1, 2016 7:53am